Loading organizations...
§ Private Profile · San Diego, CA, USA
Tr1x is a technology company.
Tr1x is a biotechnology company developing a novel class of regulatory T cell-based products designed to address autoimmune and inflammatory diseases. The company utilizes a specialized cell therapy platform to restore immune tolerance, offering a targeted approach to managing complex conditions where immune system regulation is compromised. Their work focuses on creating cellular immunotherapies with the potential to significantly impact patient care.
The company was founded in 2018 by Maria Grazia Roncarolo and David De Vries. Their founding insight centered on the critical need for new, life-changing therapies for patients grappling with autoimmune and inflammatory diseases, many of whom face substantial unmet medical needs with existing treatments. This vision propelled the establishment of Tr1x to pursue advanced cellular immunotherapy solutions.
Tr1x primarily serves patients suffering from a wide range of autoimmune and inflammatory conditions. The company’s long-term vision is to become a global leader in the development and delivery of Tr1-based immunotherapies, ultimately transforming treatment paradigms for these debilitating diseases. Their strategic focus remains on advancing this therapeutic class to improve patient outcomes worldwide.
Tr1x has raised $125.0M across 2 funding rounds.
Tr1x has raised $125.0M in total across 2 funding rounds.
Tr1x has raised $125.0M across 2 funding rounds. Most recently, it raised $50.0M Series U in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $50M Series U | — | Dimension Capital, Innovation Endeavors, LUX Capital, The Column Group | Announced |
| Jan 1, 2024 | $75M Series A | The Column Group | Dimension Capital, Innovation Endeavors, LUX Capital, Alexandria Venture Investments, Neva SGR | Announced |
Tr1x has raised $125.0M in total across 2 funding rounds.
Tr1x's investors include Dimension Capital, Innovation Endeavors, Lux Capital, The Column Group, Alexandria Venture Investments, Neva SGR.
Tr1X is a private, clinical-stage biotechnology company developing off-the-shelf allogeneic regulatory T cell-based therapies to treat and potentially cure autoimmune and inflammatory diseases.[1][2][3] Founded by scientists who discovered Type 1 regulatory T (Tr1) cells, Tr1X engineers donor-derived CD4+ T cells into Tr1-like cells (TRX cells) that restore immune tolerance by homing to inflammation sites, producing suppressive cytokines, suppressing effector responses, and inducing de-novo Tr1 cells while preserving protective immunity.[1][3][5] These therapies target high-unmet-need conditions like graft-versus-host disease (GvHD) and B-cell mediated autoimmune diseases, with lead candidates including TRX103 (Clin1 for GvHD) and TRX319 (Clin0 for B-cell mediated autoimmune inflammatory disease).[5] Headquartered in San Diego, CA, Tr1X emerged from stealth in January 2024 with a $75 million Series A led by The Column Group, NEVA SGR, and Alexandria Ventures, positioning it for rapid clinical advancement.[2][4]
The company serves patients with severe autoimmune disorders, addressing the core problem of immune system imbalance where overactive responses cause tissue damage.[1][3] Growth momentum includes being the first to advance allogeneic engineered Tr1 cell therapy into clinical trials, a robust IP portfolio, and an expanding team (11-50 employees) with open roles in clinical and immunology leadership.[2][5]
Tr1X was founded in 2018 by industry experts, including the scientists who originally discovered Type 1 regulatory T (Tr1) cells—a key subset of regulatory T cells that naturally restore immune tolerance.[1][2][5] The idea emerged from decades of T cell biology research, leveraging advances in genetic engineering to convert healthy donor CD4+ T cells into scalable, off-the-shelf Tr1-like therapies that mimic natural Tr1 function.[3][4] Early pivotal moments include building a proprietary platform for universal allogeneic Treg and CAR-Treg cells, culminating in a stealth exit with $75 million Series A funding in January 2024 to propel candidates into the clinic.[4] This backing from top investors enabled headquarters in San Diego and rapid progress to clinical-stage status, with Tr1X now pioneering the first such therapies in human trials.[1][2]
Tr1X rides the explosive growth in cell therapy for autoimmunity, shifting from oncology successes (e.g., CAR-T) to immune tolerance restoration amid rising autoimmune disease prevalence driven by genetics, environment, and aging populations.[1][3] Timing is ideal post-2024 Series A, as regulatory momentum favors allogeneic platforms for faster, cheaper scaling versus personalized therapies, with market forces like $100B+ autoimmune spend favoring curative immunomodulators.[4] Tr1X influences the ecosystem by validating Tr1 cells as a novel modality, potentially expanding to CAR-Treg combos and inspiring competitors in inflammation, while its San Diego base taps biotech hubs for talent and partnerships.[2][5]
Tr1X is poised to lead Tr1-based therapies with near-term milestones like TRX103 Phase 1 data in GvHD and TRX319 advancement, potentially unlocking blockbusters in lupus, IBD, and beyond.[5] Trends like AI-optimized engineering, combo regimens with biologics, and global autoimmune surges will accelerate adoption, evolving Tr1X from clinical pioneer to ecosystem shaper via partnerships or IPO. As the vanguard of immune reset tech, Tr1X exemplifies biotech's curative pivot, transforming "Tr1X" from discovery to disease eradication.[1][4]